Key Points
- Insider purchase: Director Stephen Pinkerton bought 520,000 shares on December 15 at GBX 6 each, a purchase valued at £31,200.
- Analyst sentiment: The stock has a consensus "Buy" rating with an average price target of GBX 17.50, while individual targets range from GBX 10 to GBX 25.
- Valuation and price action: hVIVO opened around GBX 6.67 (50-day MA GBX 6.25, 200-day MA GBX 8.68), has a market cap of £45.9m, P/E of 8.67, and a 52-week range of GBX 4.31–22.
hVIVO plc (LON:HVO - Get Free Report) insider Stephen Pinkerton acquired 520,000 shares of the business's stock in a transaction dated Monday, December 15th. The stock was purchased at an average price of GBX 6 per share, with a total value of £31,200.
hVIVO Price Performance
LON:HVO opened at GBX 6.67 on Tuesday. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The business's 50-day moving average price is GBX 6.25 and its 200 day moving average price is GBX 8.68. hVIVO plc has a 52-week low of GBX 4.31 and a 52-week high of GBX 22. The firm has a market cap of £45.86 million, a P/E ratio of 8.67 and a beta of 0.97.
hVIVO (LON:HVO - Get Free Report) last posted its quarterly earnings data on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. As a group, sell-side analysts predict that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on the stock. Peel Hunt restated an "add" rating and issued a GBX 10 price target on shares of hVIVO in a research report on Thursday, November 20th. Shore Capital reduced their price objective on hVIVO from GBX 35 to GBX 25 and set a "buy" rating for the company in a research note on Tuesday, September 23rd. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of GBX 17.50.
Read Our Latest Stock Analysis on HVO
hVIVO Company Profile
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
